Stayble Therapeutics presents at ProHearings Capital Market Day on December 1 2022

On Thursday, December 1, Stayble Therapeutics AB ("Stayble" or the "Company") will participate in ProHearing's investor event. The Company's CEO, Andreas Gerward, will give an investor presentation and answer questions in a moderated Q&A session following the presentation.

The presentation and Q&A session will be broadcast live via a link at www.prohearings.com, where you can also register to attend the event in person. Questions can be sent to the moderator by emailing info@prohearings.com. After the event, the presentation will be available on our website https://staybletherapeutics.com/.

When: December 1, 2022, at 11:00.

Where: Scandic Anglais, Stureplan, Stockholm and live at www.prohearings.com,

For more information

Andreas Gerward, CEO Stayble Therapeutics AB

Mail: andreas.gerward@stayble.se

Phone: +46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Adviser and can be reached at +46 (0) 11 32 30 732 or e-mail ca@skmg.se